 |
PDBsum entry 1ern
|
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
| |
|
DOI no:
|
Science
283:987-990
(1999)
|
|
PubMed id:
|
|
|
|
|
|
| |
|
Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation.
|
|
O.Livnah,
E.A.Stura,
S.A.Middleton,
D.L.Johnson,
L.K.Jolliffe,
I.A.Wilson.
|
|
|
|
|
| |
ABSTRACT
|
|
|
|
| |
|
|
Erythropoietin receptor (EPOR) is thought to be activated by ligand-induced
homodimerization. However, structures of agonist and antagonist peptide
complexes of EPOR, as well as an EPO-EPOR complex, have shown that the actual
dimer configuration is critical for the biological response and signal
efficiency. The crystal structure of the extracellular domain of EPOR in its
unliganded form at 2.4 angstrom resolution has revealed a dimer in which the
individual membrane-spanning and intracellular domains would be too far apart to
permit phosphorylation by JAK2. This unliganded EPOR dimer is formed from
self-association of the same key binding site residues that interact with
EPO-mimetic peptide and EPO ligands. This model for a preformed dimer on the
cell surface provides insights into the organization, activation, and plasticity
of recognition of hematopoietic cell surface receptors.
|
|
|
|
|
|
| |
Selected figure(s)
|
|
|
|
| |
|
|
|
|
Figure 1.
Fig. 1. Comparison of the unliganded and liganded EPOR
receptor dimer configurations. (A) A schematic representation of
the quaternary structure of the native EBP dimer. The two EBP
molecules form a cross-like self dimer and are shown in cyan and
gold, with their individual domains labeled D1 and D2. A close,
symmetrical interaction is formed between the two EBP molecules
on the basis of their previously determined ligand-binding
epitope regions (11). The three-residue linker between the
NH[2]-terminal  helix and
the FBN-III domains in both molecules is omitted because of the
lack of electron density in this region and the NH[2]-terminal
helices
are omitted for clarity. The D1 domains of each monomer point in
opposite directions, whereas the two D2 domains can both be
aligned toward the membrane with a rotation of 135° between
them. The membrane-proximal ends of D2 in each molecule (Thr220)
are shown by a black arrow emphasizing the 73 Å separation
between them. In the schematic of the unliganded self dimer
(right), the different scissors-like dimer configuration keeps
the intracellular ends far enough apart such that
autophosphorylation of JAK-2 cannot occur and hence other
phosphorylation events, such as on the cytoplasmic domain of the
EPOR, do not occur. (B) The quaternary structure of the EBP-EMP1
complex. The two EBP molecules are shown in gold and cyan and
the EMP1 dimer in purple. Two EMP1 peptides bind to two EBP
receptor molecules in a symmetrical manner (11). The domains are
labeled in D1 and D2 and the equivalent COOH-terminal
membrane-proximal ends of each receptor are shown by black
arrows that highlight the difference in distances and receptor
dimer configurations for the unliganded native and
EMP1-complexed EBPs. In the schematic of the liganded form
(right), EMP1 [or EPO (13)] induces a close dimer association of
both the D1 and D2 domains so that their intracellular regions
become substrates for phosphorylation by two JAK-2 molecules.
The stick figures were made with MIDAS (30).
|
|
|
|
|
|
| |
The above figure is
reprinted
by permission from the AAAs:
Science
(1999,
283,
987-990)
copyright 1999.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
|
| |
PubMed id
|
|
Reference
|
|
|
|
|
|
R.M.Bandaranayake,
D.Ungureanu,
Y.Shan,
D.E.Shaw,
O.Silvennoinen,
and
S.R.Hubbard
(2012).
Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F.
|
| |
Nat Struct Mol Biol,
19,
754-759.
|
|
|
PDB codes:
|
|
|
|
|
|
|
|
A.Cerami
(2011).
The value of failure: the discovery of TNF and its natural inhibitor erythropoietin.
|
| |
J Intern Med,
269,
8.
|
|
|
|
|
|
|
J.Biarc,
R.J.Chalkley,
A.L.Burlingame,
and
R.A.Bradshaw
(2011).
Receptor tyrosine kinase signaling - a proteomic perspective.
|
| |
Adv Enzyme Regul,
51,
293-305.
|
|
|
|
|
|
|
P.L.Kastritis,
I.H.Moal,
H.Hwang,
Z.Weng,
P.A.Bates,
A.M.Bonvin,
and
J.Janin
(2011).
A structure-based benchmark for protein-protein binding affinity.
|
| |
Protein Sci,
20,
482-491.
|
|
|
|
|
|
|
S.Abe,
R.Sasaki,
and
S.Masuda
(2011).
An extra high dose of erythropoietin fails to support the proliferation of erythropoietin dependent cell lines.
|
| |
Cytotechnology,
63,
101-109.
|
|
|
|
|
|
|
A.J.Brooks,
and
M.J.Waters
(2010).
The growth hormone receptor: mechanism of activation and clinical implications.
|
| |
Nat Rev Endocrinol,
6,
515-525.
|
|
|
|
|
|
|
D.Poger,
and
A.E.Mark
(2010).
Turning the growth hormone receptor on: evidence that hormone binding induces subunit rotation.
|
| |
Proteins,
78,
1163-1174.
|
|
|
|
|
|
|
J.Suthaus,
A.Tillmann,
I.Lorenzen,
E.Bulanova,
S.Rose-John,
and
J.Scheller
(2010).
Forced homo- and heterodimerization of all gp130-type receptor complexes leads to constitutive ligand-independent signaling and cytokine-independent growth.
|
| |
Mol Biol Cell,
21,
2797-2807.
|
|
|
|
|
|
|
M.L.Radhakrishnan,
and
B.Tidor
(2010).
Cellular level models as tools for cytokine design.
|
| |
Biotechnol Prog,
26,
919-937.
|
|
|
|
|
|
|
M.S.Kuhns,
A.T.Girvin,
L.O.Klein,
R.Chen,
K.D.Jensen,
E.W.Newell,
J.B.Huppa,
B.F.Lillemeier,
M.Huse,
Y.H.Chien,
K.C.Garcia,
and
M.M.Davis
(2010).
Evidence for a functional sidedness to the alphabetaTCR.
|
| |
Proc Natl Acad Sci U S A,
107,
5094-5099.
|
|
|
|
|
|
|
R.Stasi,
J.Bosworth,
E.Rhodes,
M.S.Shannon,
F.Willis,
and
E.C.Gordon-Smith
(2010).
Thrombopoietic agents.
|
| |
Blood Rev,
24,
179-190.
|
|
|
|
|
|
|
S.I.Yoon,
B.C.Jones,
N.J.Logsdon,
B.D.Harris,
A.Deshpande,
S.Radaeva,
B.A.Halloran,
B.Gao,
and
M.R.Walter
(2010).
Structure and mechanism of receptor sharing by the IL-10R2 common chain.
|
| |
Structure,
18,
638-648.
|
|
|
PDB code:
|
|
|
|
|
|
|
|
T.J.Cammett,
S.J.Jun,
E.B.Cohen,
F.N.Barrera,
D.M.Engelman,
and
D.Dimaio
(2010).
Construction and genetic selection of small transmembrane proteins that activate the human erythropoietin receptor.
|
| |
Proc Natl Acad Sci U S A,
107,
3447-3452.
|
|
|
|
|
|
|
C.Marty,
R.Chaligné,
C.Lacout,
S.N.Constantinescu,
W.Vainchenker,
and
J.L.Villeval
(2009).
Ligand-independent thrombopoietin mutant receptor requires cell surface localization for endogenous activity.
|
| |
J Biol Chem,
284,
11781-11791.
|
|
|
|
|
|
|
F.Morceau,
M.Dicato,
and
M.Diederich
(2009).
Pro-inflammatory cytokine-mediated anemia: regarding molecular mechanisms of erythropoiesis.
|
| |
Mediators Inflamm,
2009,
405016.
|
|
|
|
|
|
|
H.Ogawa,
Y.Qiu,
L.Huang,
S.W.Tam-Chang,
H.S.Young,
and
K.S.Misono
(2009).
Structure of the atrial natriuretic peptide receptor extracellular domain in the unbound and hormone-bound states by single-particle electron microscopy.
|
| |
FEBS J,
276,
1347-1355.
|
|
|
|
|
|
|
J.Ding,
H.Komatsu,
S.Iida,
H.Yano,
S.Kusumoto,
A.Inagaki,
F.Mori,
M.Ri,
A.Ito,
A.Wakita,
T.Ishida,
M.Nitta,
and
R.Ueda
(2009).
The Asn505 mutation of the c-MPL gene, which causes familial essential thrombocythemia, induces autonomous homodimerization of the c-Mpl protein due to strong amino acid polarity.
|
| |
Blood,
114,
3325-3328.
|
|
|
|
|
|
|
K.Kaushansky
(2009).
Molecular mechanisms of thrombopoietin signaling.
|
| |
J Thromb Haemost,
7,
235-238.
|
|
|
|
|
|
|
M.Perugini,
A.Varelias,
T.Sadlon,
and
R.J.D'Andrea
(2009).
Hematopoietic growth factor mimetics: from concept to clinic.
|
| |
Cytokine Growth Factor Rev,
20,
87-94.
|
|
|
|
|
|
|
M.Schilling,
T.Maiwald,
S.Hengl,
D.Winter,
C.Kreutz,
W.Kolch,
W.D.Lehmann,
J.Timmer,
and
U.Klingmüller
(2009).
Theoretical and experimental analysis links isoform-specific ERK signalling to cell fate decisions.
|
| |
Mol Syst Biol,
5,
334.
|
|
|
|
|
|
|
P.Sathyanarayana,
E.Houde,
D.Marshall,
A.Volk,
D.Makropoulos,
C.Emerson,
A.Pradeep,
P.J.Bugelski,
and
D.M.Wojchowski
(2009).
CNTO 530 functions as a potent EPO mimetic via unique sustained effects on bone marrow proerythroblast pools.
|
| |
Blood,
113,
4955-4962.
|
|
|
|
|
|
|
W.Liu,
M.Kawahara,
H.Ueda,
and
T.Nagamune
(2009).
The influence of domain structures on the signal transduction of chimeric receptors derived from the erythropoietin receptor.
|
| |
J Biochem,
145,
575-584.
|
|
|
|
|
|
|
Y.Jia,
R.Warin,
X.Yu,
R.Epstein,
and
C.T.Noguchi
(2009).
Erythropoietin signaling promotes transplanted progenitor cell survival.
|
| |
FASEB J,
23,
3089-3099.
|
|
|
|
|
|
|
Y.L.Xie,
S.A.Hassan,
A.M.Qazi,
C.H.Tsai-Morris,
and
M.L.Dufau
(2009).
Intramolecular disulfide bonds of the prolactin receptor short form are required for its inhibitory action on the function of the long form of the receptor.
|
| |
Mol Cell Biol,
29,
2546-2555.
|
|
|
|
|
|
|
C.T.Noguchi,
L.Wang,
H.M.Rogers,
R.Teng,
and
Y.Jia
(2008).
Survival and proliferative roles of erythropoietin beyond the erythroid lineage.
|
| |
Expert Rev Mol Med,
10,
e36.
|
|
|
|
|
|
|
E.W.Debler,
Y.Ma,
H.S.Seo,
K.C.Hsia,
T.R.Noriega,
G.Blobel,
and
A.Hoelz
(2008).
A fence-like coat for the nuclear pore membrane.
|
| |
Mol Cell,
32,
815-826.
|
|
|
PDB codes:
|
|
|
|
|
|
|
|
F.Shen,
and
S.L.Gaffen
(2008).
Structure-function relationships in the IL-17 receptor: implications for signal transduction and therapy.
|
| |
Cytokine,
41,
92.
|
|
|
|
|
|
|
G.Skiniotis,
P.J.Lupardus,
M.Martick,
T.Walz,
and
K.C.Garcia
(2008).
Structural organization of a full-length gp130/LIF-R cytokine receptor transmembrane complex.
|
| |
Mol Cell,
31,
737-748.
|
|
|
PDB code:
|
|
|
|
|
|
|
|
H.M.Rogers,
X.Yu,
J.Wen,
R.Smith,
E.Fibach,
and
C.T.Noguchi
(2008).
Hypoxia alters progression of the erythroid program.
|
| |
Exp Hematol,
36,
17-27.
|
|
|
|
|
|
|
J.Vera,
T.Millat,
W.Kolch,
and
O.Wolkenhauer
(2008).
Dynamics of receptor and protein transducer homodimerisation.
|
| |
BMC Syst Biol,
2,
92.
|
|
|
|
|
|
|
M.Zaks-Zilberman,
A.E.Harrington,
T.Ishino,
and
I.M.Chaiken
(2008).
Interleukin-5 receptor subunit oligomerization and rearrangement revealed by fluorescence resonance energy transfer imaging.
|
| |
J Biol Chem,
283,
13398-13406.
|
|
|
|
|
|
|
P.Sathyanarayana,
A.Dev,
J.Fang,
E.Houde,
O.Bogacheva,
O.Bogachev,
M.Menon,
S.Browne,
A.Pradeep,
C.Emerson,
and
D.M.Wojchowski
(2008).
EPO receptor circuits for primary erythroblast survival.
|
| |
Blood,
111,
5390-5399.
|
|
|
|
|
|
|
T.Zhou,
C.Xu,
M.He,
and
Y.Sun
(2008).
Upregulation of erythropoietin receptor in human prostate carcinoma and high-grade prostatic intraepithelial neoplasia.
|
| |
Prostate Cancer Prostatic Dis,
11,
143-147.
|
|
|
|
|
|
|
W.Liu,
M.Kawahara,
H.Ueda,
and
T.Nagamune
(2008).
Construction of a fluorescein-responsive chimeric receptor with strict ligand dependency.
|
| |
Biotechnol Bioeng,
101,
975-984.
|
|
|
|
|
|
|
W.M.Bernhardt,
and
K.U.Eckardt
(2008).
Physiological basis for the use of erythropoietin in critically ill patients at risk for acute kidney injury.
|
| |
Curr Opin Crit Care,
14,
621-626.
|
|
|
|
|
|
|
W.Vainchenker,
A.Dusa,
and
S.N.Constantinescu
(2008).
JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies.
|
| |
Semin Cell Dev Biol,
19,
385-393.
|
|
|
|
|
|
|
Y.Malka,
T.Hornakova,
Y.Royer,
L.Knoops,
J.C.Renauld,
S.N.Constantinescu,
and
Y.I.Henis
(2008).
Ligand-independent homomeric and heteromeric complexes between interleukin-2 or -9 receptor subunits and the gamma chain.
|
| |
J Biol Chem,
283,
33569-33577.
|
|
|
|
|
|
|
Z.Li,
J.J.Strunk,
P.Lamken,
J.Piehler,
and
T.Walz
(2008).
The EM structure of a type I interferon-receptor complex reveals a novel mechanism for cytokine signaling.
|
| |
J Mol Biol,
377,
715-724.
|
|
|
|
|
|
|
B.M.Dattilo,
G.Fritz,
E.Leclerc,
C.W.Kooi,
C.W.Heizmann,
and
W.J.Chazin
(2007).
The extracellular region of the receptor for advanced glycation end products is composed of two independent structural units.
|
| |
Biochemistry,
46,
6957-6970.
|
|
|
|
|
|
|
C.T.Noguchi,
P.Asavaritikrai,
R.Teng,
and
Y.Jia
(2007).
Role of erythropoietin in the brain.
|
| |
Crit Rev Oncol Hematol,
64,
159-171.
|
|
|
|
|
|
|
D.J.Kuter
(2007).
New thrombopoietic growth factors.
|
| |
Blood,
109,
4607-4616.
|
|
|
|
|
|
|
E.Latz,
A.Verma,
A.Visintin,
M.Gong,
C.M.Sirois,
D.C.Klein,
B.G.Monks,
C.J.McKnight,
M.S.Lamphier,
W.P.Duprex,
T.Espevik,
and
D.T.Golenbock
(2007).
Ligand-induced conformational changes allosterically activate Toll-like receptor 9.
|
| |
Nat Immunol,
8,
772-779.
|
|
|
|
|
|
|
J.M.Kramer,
W.Hanel,
F.Shen,
N.Isik,
J.P.Malone,
A.Maitra,
W.Sigurdson,
D.Swart,
J.Tocker,
T.Jin,
and
S.L.Gaffen
(2007).
Cutting edge: identification of a pre-ligand assembly domain (PLAD) and ligand binding site in the IL-17 receptor.
|
| |
J Immunol,
179,
6379-6383.
|
|
|
|
|
|
|
L.Robb
(2007).
Cytokine receptors and hematopoietic differentiation.
|
| |
Oncogene,
26,
6715-6723.
|
|
|
|
|
|
|
M.E.Call,
and
K.W.Wucherpfennig
(2007).
Common themes in the assembly and architecture of activating immune receptors.
|
| |
Nat Rev Immunol,
7,
841-850.
|
|
|
|
|
|
|
M.Socolovsky
(2007).
Molecular insights into stress erythropoiesis.
|
| |
Curr Opin Hematol,
14,
215-224.
|
|
|
|
|
|
|
O.Ravid,
I.Shams,
N.Ben Califa,
E.Nevo,
A.Avivi,
and
D.Neumann
(2007).
An extracellular region of the erythropoietin receptor of the subterranean blind mole rat Spalax enhances receptor maturation.
|
| |
Proc Natl Acad Sci U S A,
104,
14360-14365.
|
|
|
|
|
|
|
O.Vadas,
and
K.Rose
(2007).
Multivalency - a way to enhance binding avidities and bioactivity - preliminary applications to EPO.
|
| |
J Pept Sci,
13,
581-587.
|
|
|
|
|
|
|
P.Katavetin,
K.Tungsanga,
S.Eiam-Ong,
and
M.Nangaku
(2007).
Antioxidative effects of erythropoietin.
|
| |
Kidney Int Suppl,
(),
S10-S15.
|
|
|
|
|
|
|
W.Jelkmann
(2007).
Erythropoietin after a century of research: younger than ever.
|
| |
Eur J Haematol,
78,
183-205.
|
|
|
|
|
|
|
A.Khwaja
(2006).
The role of Janus kinases in haemopoiesis and haematological malignancy.
|
| |
Br J Haematol,
134,
366-384.
|
|
|
|
|
|
|
A.L.Stiegler,
S.J.Burden,
and
S.R.Hubbard
(2006).
Crystal structure of the agrin-responsive immunoglobulin-like domains 1 and 2 of the receptor tyrosine kinase MuSK.
|
| |
J Mol Biol,
364,
424-433.
|
|
|
PDB code:
|
|
|
|
|
|
|
|
C.D.Krause,
N.Lavnikova,
J.Xie,
E.Mei,
O.V.Mirochnitchenko,
Y.Jia,
R.M.Hochstrasser,
and
S.Pestka
(2006).
Preassembly and ligand-induced restructuring of the chains of the IFN-gamma receptor complex: the roles of Jak kinases, Stat1 and the receptor chains.
|
| |
Cell Res,
16,
55-69.
|
|
|
|
|
|
|
C.Stuhlmann-Laeisz,
S.Lang,
A.Chalaris,
P.Krzysztof,
S.Enge,
J.Eichler,
U.Klingmüller,
M.Samuel,
M.Ernst,
S.Rose-John,
and
J.Scheller
(2006).
Forced dimerization of gp130 leads to constitutive STAT3 activation, cytokine-independent growth, and blockade of differentiation of embryonic stem cells.
|
| |
Mol Biol Cell,
17,
2986-2995.
|
|
|
|
|
|
|
J.M.Kramer,
L.Yi,
F.Shen,
A.Maitra,
X.Jiao,
T.Jin,
and
S.L.Gaffen
(2006).
Evidence for ligand-independent multimerization of the IL-17 receptor.
|
| |
J Immunol,
176,
711-715.
|
|
|
|
|
|
|
K.Kaushansky
(2006).
Hematopoietic growth factors, signaling and the chronic myeloproliferative disorders.
|
| |
Cytokine Growth Factor Rev,
17,
423-430.
|
|
|
|
|
|
|
M.E.Nelson,
and
D.P.Steensma
(2006).
JAK2 V617F in myeloid disorders: what do we know now, and where are we headed?
|
| |
Leuk Lymphoma,
47,
177-194.
|
|
|
|
|
|
|
M.P.Menon,
J.Fang,
and
D.M.Wojchowski
(2006).
Core erythropoietin receptor signals for late erythroblast development.
|
| |
Blood,
107,
2662-2672.
|
|
|
|
|
|
|
M.P.Menon,
V.Karur,
O.Bogacheva,
O.Bogachev,
B.Cuetara,
and
D.M.Wojchowski
(2006).
Signals for stress erythropoiesis are integrated via an erythropoietin receptor-phosphotyrosine-343-Stat5 axis.
|
| |
J Clin Invest,
116,
683-694.
|
|
|
|
|
|
|
S.Kjaer,
K.Kurokawa,
M.Perrinjaquet,
C.Abrescia,
and
C.F.Ibáñez
(2006).
Self-association of the transmembrane domain of RET underlies oncogenic activation by MEN2A mutations.
|
| |
Oncogene,
25,
7086-7095.
|
|
|
|
|
|
|
S.M.Kumar,
H.Yu,
D.Fong,
G.Acs,
and
X.Xu
(2006).
Erythropoietin activates the phosphoinositide 3-kinase/Akt pathway in human melanoma cells.
|
| |
Melanoma Res,
16,
275-283.
|
|
|
|
|
|
|
Y.Liu,
R.Pop,
C.Sadegh,
C.Brugnara,
V.H.Haase,
and
M.Socolovsky
(2006).
Suppression of Fas-FasL coexpression by erythropoietin mediates erythroblast expansion during the erythropoietic stress response in vivo.
|
| |
Blood,
108,
123-133.
|
|
|
|
|
|
|
A.Schroers,
O.Hecht,
K.J.Kallen,
M.Pachta,
S.Rose-John,
and
J.Grötzinger
(2005).
Dynamics of the gp130 cytokine complex: a model for assembly on the cellular membrane.
|
| |
Protein Sci,
14,
783-790.
|
|
|
|
|
|
|
H.M.Hermanns,
G.Müller-Newen,
P.C.Heinrich,
and
S.Haan
(2005).
Bow to your partner for signaling.
|
| |
Nat Struct Mol Biol,
12,
476-478.
|
|
|
|
|
|
|
J.P.Pin,
J.Kniazeff,
J.Liu,
V.Binet,
C.Goudet,
P.Rondard,
and
L.Prézeau
(2005).
Allosteric functioning of dimeric class C G-protein-coupled receptors.
|
| |
FEBS J,
272,
2947-2955.
|
|
|
|
|
|
|
K.Kaushansky
(2005).
The molecular mechanisms that control thrombopoiesis.
|
| |
J Clin Invest,
115,
3339-3347.
|
|
|
|
|
|
|
M.Brines,
and
A.Cerami
(2005).
Emerging biological roles for erythropoietin in the nervous system.
|
| |
Nat Rev Neurosci,
6,
484-494.
|
|
|
|
|
|
|
M.E.Call,
and
K.W.Wucherpfennig
(2005).
The T cell receptor: critical role of the membrane environment in receptor assembly and function.
|
| |
Annu Rev Immunol,
23,
101-125.
|
|
|
|
|
|
|
M.O.Arcasoy,
and
A.F.Karayal
(2005).
Erythropoietin hypersensitivity in primary familial and congenital polycythemia: role of tyrosines Y285 and Y344 in erythropoietin receptor cytoplasmic domain.
|
| |
Biochim Biophys Acta,
1740,
17-28.
|
|
|
|
|
|
|
M.O.Arcasoy,
K.Amin,
R.T.Vollmer,
X.Jiang,
W.Demark-Wahnefried,
and
Z.A.Haroon
(2005).
Erythropoietin and erythropoietin receptor expression in human prostate cancer.
|
| |
Mod Pathol,
18,
421-430.
|
|
|
|
|
|
|
R.J.Brown,
J.J.Adams,
R.A.Pelekanos,
Y.Wan,
W.J.McKinstry,
K.Palethorpe,
R.M.Seeber,
T.A.Monks,
K.A.Eidne,
M.W.Parker,
and
M.J.Waters
(2005).
Model for growth hormone receptor activation based on subunit rotation within a receptor dimer.
|
| |
Nat Struct Mol Biol,
12,
814-821.
|
|
|
PDB code:
|
|
|
|
|
|
|
|
K.C.Leung
(2004).
Regulation of cytokine receptor signaling by nuclear hormone receptors: a new paradigm for receptor interaction.
|
| |
DNA Cell Biol,
23,
463-474.
|
|
|
|
|
|
|
M.Brines,
G.Grasso,
F.Fiordaliso,
A.Sfacteria,
P.Ghezzi,
M.Fratelli,
R.Latini,
Q.W.Xie,
J.Smart,
C.J.Su-Rick,
E.Pobre,
D.Diaz,
D.Gomez,
C.Hand,
T.Coleman,
and
A.Cerami
(2004).
Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor.
|
| |
Proc Natl Acad Sci U S A,
101,
14907-14912.
|
|
|
|
|
|
|
M.D.Feese,
T.Tamada,
Y.Kato,
Y.Maeda,
M.Hirose,
Y.Matsukura,
H.Shigematsu,
T.Muto,
A.Matsumoto,
H.Watarai,
K.Ogami,
T.Tahara,
T.Kato,
H.Miyazaki,
and
R.Kuroki
(2004).
Structure of the receptor-binding domain of human thrombopoietin determined by complexation with a neutralizing antibody fragment.
|
| |
Proc Natl Acad Sci U S A,
101,
1816-1821.
|
|
|
PDB codes:
|
|
|
|
|
|
|
|
M.E.Call,
J.Pyrdol,
and
K.W.Wucherpfennig
(2004).
Stoichiometry of the T-cell receptor-CD3 complex and key intermediates assembled in the endoplasmic reticulum.
|
| |
EMBO J,
23,
2348-2357.
|
|
|
|
|
|
|
P.Ruchala,
G.Varadi,
T.Ishino,
J.Scibek,
M.Bhattacharya,
C.Urbina,
D.V.Ryk,
I.Uings,
and
I.Chaiken
(2004).
Cyclic peptide interleukin 5 antagonists mimic CD turn recognition epitope for receptor alpha.
|
| |
Biopolymers,
73,
556-568.
|
|
|
|
|
|
|
T.Van Maerken,
K.Hunninck,
L.Callewaert,
Y.Benoit,
G.Laureys,
and
J.Verlooy
(2004).
Familial and congenital polycythemias: a diagnostic approach.
|
| |
J Pediatr Hematol Oncol,
26,
407-416.
|
|
|
|
|
|
|
W.Jelkmann
(2004).
Molecular biology of erythropoietin.
|
| |
Intern Med,
43,
649-659.
|
|
|
|
|
|
|
W.Sebald,
J.Nickel,
J.L.Zhang,
and
T.D.Mueller
(2004).
Molecular recognition in bone morphogenetic protein (BMP)/receptor interaction.
|
| |
Biol Chem,
385,
697-710.
|
|
|
|
|
|
|
B.Malissen
(2003).
An evolutionary and structural perspective on T cell antigen receptor function.
|
| |
Immunol Rev,
191,
7.
|
|
|
|
|
|
|
F.Lühder,
Y.Huang,
K.M.Dennehy,
C.Guntermann,
I.Müller,
E.Winkler,
T.Kerkau,
S.Ikemizu,
S.J.Davis,
T.Hanke,
and
T.Hünig
(2003).
Topological requirements and signaling properties of T cell-activating, anti-CD28 antibody superagonists.
|
| |
J Exp Med,
197,
955-966.
|
|
|
|
|
|
|
H.Jingami,
S.Nakanishi,
and
K.Morikawa
(2003).
Structure of the metabotropic glutamate receptor.
|
| |
Curr Opin Neurobiol,
13,
271-278.
|
|
|
|
|
|
|
I.Lemmens,
S.Eyckerman,
L.Zabeau,
D.Catteeuw,
E.Vertenten,
K.Verschueren,
D.Huylebroeck,
J.Vandekerckhove,
and
J.Tavernier
(2003).
Heteromeric MAPPIT: a novel strategy to study modification-dependent protein-protein interactions in mammalian cells.
|
| |
Nucleic Acids Res,
31,
e75.
|
|
|
|
|
|
|
J.P.Pin,
T.Galvez,
and
L.Prézeau
(2003).
Evolution, structure, and activation mechanism of family 3/C G-protein-coupled receptors.
|
| |
Pharmacol Ther,
98,
325-354.
|
|
|
|
|
|
|
M.Kawahara,
H.Ueda,
S.Morita,
K.Tsumoto,
I.Kumagai,
and
T.Nagamune
(2003).
Bypassing antibiotic selection: positive screening of genetically modified cells with an antigen-dependent proliferation switch.
|
| |
Nucleic Acids Res,
31,
e32.
|
|
|
|
|
|
|
N.Seubert,
Y.Royer,
J.Staerk,
K.F.Kubatzky,
V.Moucadel,
S.Krishnakumar,
S.O.Smith,
and
S.N.Constantinescu
(2003).
Active and inactive orientations of the transmembrane and cytosolic domains of the erythropoietin receptor dimer.
|
| |
Mol Cell,
12,
1239-1250.
|
|
|
|
|
|
|
T.B.Thompson,
T.K.Woodruff,
and
T.S.Jardetzky
(2003).
Structures of an ActRIIB:activin A complex reveal a novel binding mode for TGF-beta ligand:receptor interactions.
|
| |
EMBO J,
22,
1555-1566.
|
|
|
PDB codes:
|
|
|
|
|
|
|
|
W.Sebald,
and
T.D.Mueller
(2003).
The interaction of BMP-7 and ActRII implicates a new mode of receptor assembly.
|
| |
Trends Biochem Sci,
28,
518-521.
|
|
|
|
|
|
|
A.E.Geddis,
H.M.Linden,
and
K.Kaushansky
(2002).
Thrombopoietin: a pan-hematopoietic cytokine.
|
| |
Cytokine Growth Factor Rev,
13,
61-73.
|
|
|
|
|
|
|
A.P.Maxwell
(2002).
Novel erythropoiesis-stimulating protein in the management of the anemia of chronic renal failure.
|
| |
Kidney Int,
62,
720-729.
|
|
|
|
|
|
|
J.C.Hombría,
and
S.Brown
(2002).
The fertile field of Drosophila Jak/STAT signalling.
|
| |
Curr Biol,
12,
R569-R575.
|
|
|
|
|
|
|
J.Gent,
P.van Kerkhof,
M.Roza,
G.Bu,
and
G.J.Strous
(2002).
Ligand-independent growth hormone receptor dimerization occurs in the endoplasmic reticulum and is required for ubiquitin system-dependent endocytosis.
|
| |
Proc Natl Acad Sci U S A,
99,
9858-9863.
|
|
|
|
|
|
|
K.Morikawa
(2002).
[Ligand recognition mechanism of G-CSF receptor and metabotropic glutamate receptor]
|
| |
Yakugaku Zasshi,
122,
855-868.
|
|
|
|
|
|
|
K.Natarajan,
N.Dimasi,
J.Wang,
R.A.Mariuzza,
and
D.H.Margulies
(2002).
Structure and function of natural killer cell receptors: multiple molecular solutions to self, nonself discrimination.
|
| |
Annu Rev Immunol,
20,
853-885.
|
|
|
|
|
|
|
M.R.Gold
(2002).
To make antibodies or not: signaling by the B-cell antigen receptor.
|
| |
Trends Pharmacol Sci,
23,
316-324.
|
|
|
|
|
|
|
P.S.Mischel,
J.A.Umbach,
S.Eskandari,
S.G.Smith,
C.B.Gundersen,
and
G.A.Zampighi
(2002).
Nerve growth factor signals via preexisting TrkA receptor oligomers.
|
| |
Biophys J,
83,
968-976.
|
|
|
|
|
|
|
R.Adar,
E.Monsonego-Ornan,
P.David,
and
A.Yayon
(2002).
Differential activation of cysteine-substitution mutants of fibroblast growth factor receptor 3 is determined by cysteine localization.
|
| |
J Bone Miner Res,
17,
860-868.
|
|
|
|
|
|
|
S.Angers,
A.Salahpour,
and
M.Bouvier
(2002).
Dimerization: an emerging concept for G protein-coupled receptor ontogeny and function.
|
| |
Annu Rev Pharmacol Toxicol,
42,
409-435.
|
|
|
|
|
|
|
C.H.Heldin
(2001).
Signal transduction: multiple pathways, multiple options for therapy.
|
| |
Stem Cells,
19,
295-303.
|
|
|
|
|
|
|
C.J.Bagley,
J.M.Woodcock,
M.A.Guthridge,
F.C.Stomski,
and
A.F.Lopez
(2001).
Structural and functional hot spots in cytokine receptors.
|
| |
Int J Hematol,
73,
299-307.
|
|
|
|
|
|
|
H.Plun-Favreau,
G.Elson,
M.Chabbert,
J.Froger,
O.deLapeyrière,
E.Lelièvre,
C.Guillet,
J.Hermann,
J.F.Gauchat,
H.Gascan,
and
S.Chevalier
(2001).
The ciliary neurotrophic factor receptor alpha component induces the secretion of and is required for functional responses to cardiotrophin-like cytokine.
|
| |
EMBO J,
20,
1692-1703.
|
|
|
|
|
|
|
J.G.Altin,
F.A.White,
and
C.J.Easton
(2001).
Synthesis of the chelator lipid nitrilotriacetic acid ditetradecylamine (NTA-DTDA) and its use with the IAsys biosensor to study receptor-ligand interactions on model membranes.
|
| |
Biochim Biophys Acta,
1513,
131-148.
|
|
|
|
|
|
|
M.Gropp,
Y.Strausz,
M.Gross,
and
G.Glaser
(2001).
Regulation of Escherichia coli RelA requires oligomerization of the C-terminal domain.
|
| |
J Bacteriol,
183,
570-579.
|
|
|
|
|
|
|
M.Reth
(2001).
Oligomeric antigen receptors: a new view on signaling for the selection of lymphocytes.
|
| |
Trends Immunol,
22,
356-360.
|
|
|
|
|
|
|
P.D.Carr,
S.E.Gustin,
A.P.Church,
J.M.Murphy,
S.C.Ford,
D.A.Mann,
D.M.Woltring,
I.Walker,
D.L.Ollis,
and
I.G.Young
(2001).
Structure of the complete extracellular domain of the common beta subunit of the human GM-CSF, IL-3, and IL-5 receptors reveals a novel dimer configuration.
|
| |
Cell,
104,
291-300.
|
|
|
PDB code:
|
|
|
|
|
|
|
|
S.N.Constantinescu,
L.J.Huang,
H.Nam,
and
H.F.Lodish
(2001).
The erythropoietin receptor cytosolic juxtamembrane domain contains an essential, precisely oriented, hydrophobic motif.
|
| |
Mol Cell,
7,
377-385.
|
|
|
|
|
|
|
S.N.Constantinescu,
T.Keren,
M.Socolovsky,
H.Nam,
Y.I.Henis,
and
H.F.Lodish
(2001).
Ligand-independent oligomerization of cell-surface erythropoietin receptor is mediated by the transmembrane domain.
|
| |
Proc Natl Acad Sci U S A,
98,
4379-4384.
|
|
|
|
|
|
|
C.A.Bell,
J.A.Tynan,
K.C.Hart,
A.N.Meyer,
S.C.Robertson,
and
D.J.Donoghue
(2000).
Rotational coupling of the transmembrane and kinase domains of the Neu receptor tyrosine kinase.
|
| |
Mol Biol Cell,
11,
3589-3599.
|
|
|
|
|
|
|
C.Yoon,
S.C.Johnston,
J.Tang,
M.Stahl,
J.F.Tobin,
and
W.S.Somers
(2000).
Charged residues dominate a unique interlocking topography in the heterodimeric cytokine interleukin-12.
|
| |
EMBO J,
19,
3530-3541.
|
|
|
PDB codes:
|
|
|
|
|
|
|
|
E.J.Sundberg,
and
R.A.Mariuzza
(2000).
Luxury accommodations: the expanding role of structural plasticity in protein-protein interactions.
|
| |
Structure,
8,
R137-R142.
|
|
|
|
|
|
|
E.Y.Jones
(2000).
The tumour necrosis factor receptor family: life or death choices.
|
| |
Curr Opin Struct Biol,
10,
644-648.
|
|
|
|
|
|
|
F.P.Ottensmeyer,
D.R.Beniac,
R.Z.Luo,
and
C.C.Yip
(2000).
Mechanism of transmembrane signaling: insulin binding and the insulin receptor.
|
| |
Biochemistry,
39,
12103-12112.
|
|
|
|
|
|
|
G.De Crescenzo,
S.Grothe,
R.Lortie,
M.T.Debanne,
and
M.O'Connor-McCourt
(2000).
Real-time kinetic studies on the interaction of transforming growth factor alpha with the epidermal growth factor receptor extracellular domain reveal a conformational change model.
|
| |
Biochemistry,
39,
9466-9476.
|
|
|
|
|
|
|
J.Bravo,
and
J.K.Heath
(2000).
Receptor recognition by gp130 cytokines.
|
| |
EMBO J,
19,
2399-2411.
|
|
|
|
|
|
|
J.Schlessinger,
A.N.Plotnikov,
O.A.Ibrahimi,
A.V.Eliseenkova,
B.K.Yeh,
A.Yayon,
R.J.Linhardt,
and
M.Mohammadi
(2000).
Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization.
|
| |
Mol Cell,
6,
743-750.
|
|
|
PDB code:
|
|
|
|
|
|
|
|
L.Cosenza,
A.Rosenbach,
J.V.White,
J.R.Murphy,
and
T.Smith
(2000).
Comparative model building of interleukin-7 using interleukin-4 as a template: a structural hypothesis that displays atypical surface chemistry in helix D important for receptor activation.
|
| |
Protein Sci,
9,
916-926.
|
|
|
|
|
|
|
L.Gilboa,
A.Nohe,
T.Geissendörfer,
W.Sebald,
Y.I.Henis,
and
P.Knaus
(2000).
Bone morphogenetic protein receptor complexes on the surface of live cells: a new oligomerization mode for serine/threonine kinase receptors.
|
| |
Mol Biol Cell,
11,
1023-1035.
|
|
|
|
|
|
|
M.C.Deller,
and
E.Yvonne Jones
(2000).
Cell surface receptors.
|
| |
Curr Opin Struct Biol,
10,
213-219.
|
|
|
|
|
|
|
R.A.Ortmann,
T.Cheng,
R.Visconti,
D.M.Frucht,
and
J.J.O'Shea
(2000).
Janus kinases and signal transducers and activators of transcription: their roles in cytokine signaling, development and immunoregulation.
|
| |
Arthritis Res,
2,
16-32.
|
|
|
|
|
|
|
R.Sasaki,
S.Masuda,
and
M.Nagao
(2000).
Erythropoietin: multiple physiological functions and regulation of biosynthesis.
|
| |
Biosci Biotechnol Biochem,
64,
1775-1793.
|
|
|
|
|
|
|
S.G.Miller
(2000).
Discovery of cytokine mimics using cell-based systems.
|
| |
Drug Discov Today,
5,
77-83.
|
|
|
|
|
|
|
W.W.Schamel,
and
M.Reth
(2000).
Monomeric and oligomeric complexes of the B cell antigen receptor.
|
| |
Immunity,
13,
5.
|
|
|
|
|
|
|
A.C.Ward,
Y.M.van Aesch,
J.Gits,
A.M.Schelen,
J.P.de Koning,
D.van Leeuwen,
M.H.Freedman,
and
I.P.Touw
(1999).
Novel point mutation in the extracellular domain of the granulocyte colony-stimulating factor (G-CSF) receptor in a case of severe congenital neutropenia hyporesponsive to G-CSF treatment.
|
| |
J Exp Med,
190,
497-507.
|
|
|
|
|
|
|
G.Jiang,
and
T.Hunter
(1999).
Receptor signaling: when dimerization is not enough.
|
| |
Curr Biol,
9,
R568-R571.
|
|
|
|
|
|
|
I.A.Wilson,
and
L.K.Jolliffe
(1999).
The structure, organization, activation and plasticity of the erythropoietin receptor.
|
| |
Curr Opin Struct Biol,
9,
696-704.
|
|
|
|
|
|
|
J.Grötzinger,
T.Kernebeck,
K.J.Kallen,
and
S.Rose-John
(1999).
IL-6 type cytokine receptor complexes: hexamer, tetramer or both?
|
| |
Biol Chem,
380,
803-813.
|
|
|
|
|
|
|
K.D.Wittrup
(1999).
Phage on display.
|
| |
Trends Biotechnol,
17,
423-424.
|
|
|
|
|
|
|
K.E.Mogensen,
M.Lewerenz,
J.Reboul,
G.Lutfalla,
and
G.Uzé
(1999).
The type I interferon receptor: structure, function, and evolution of a family business.
|
| |
J Interferon Cytokine Res,
19,
1069-1098.
|
|
|
|
|
|
|
R.K.Goyal,
and
G.D.Longmore
(1999).
Abnormalities of cytokine receptor signalling contributing to diseases of red blood cell production.
|
| |
Ann Med,
31,
208-216.
|
|
|
|
|
|
|
R.M.Arduini,
K.L.Strauch,
L.A.Runkel,
M.M.Carlson,
X.Hronowski,
S.F.Foley,
C.N.Young,
W.Cheng,
P.S.Hochman,
and
D.P.Baker
(1999).
Characterization of a soluble ternary complex formed between human interferon-beta-1a and its receptor chains.
|
| |
Protein Sci,
8,
1867-1877.
|
|
|
|
|
|
|
S.M.McWhirter,
S.S.Pullen,
B.G.Werneburg,
M.E.Labadia,
R.H.Ingraham,
J.J.Crute,
M.R.Kehry,
and
T.Alber
(1999).
Structural and biochemical analysis of signal transduction by the TRAF family of adapter proteins.
|
| |
Cold Spring Harb Symp Quant Biol,
64,
551-562.
|
|
|
|
|
|
|
S.N.Behncken,
and
M.J.Waters
(1999).
Molecular recognition events involved in the activation of the growth hormone receptor by growth hormone.
|
| |
J Mol Recognit,
12,
355-362.
|
|
|
|
|
|
|
S.N.Constantinescu,
X.Liu,
W.Beyer,
A.Fallon,
S.Shekar,
Y.I.Henis,
S.O.Smith,
and
H.F.Lodish
(1999).
Activation of the erythropoietin receptor by the gp55-P viral envelope protein is determined by a single amino acid in its transmembrane domain.
|
| |
EMBO J,
18,
3334-3347.
|
|
|
|
|
|
|
Y.H.Ding,
B.M.Baker,
D.N.Garboczi,
W.E.Biddison,
and
D.C.Wiley
(1999).
Four A6-TCR/peptide/HLA-A2 structures that generate very different T cell signals are nearly identical.
|
| |
Immunity,
11,
45-56.
|
|
|
PDB codes:
|
|
|
|
|
|
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
codes are
shown on the right.
|
|
Links
